Top of this page
Skip navigation, go straight to the content
Categories
UCB Stories
-
Half-time analysis: UCB outlook for 2018 confirmed
Posted by 25-Jul-2018
-
Three months interim report: what are the highlights?
Posted by 25-Apr-2018
-
Laying a foundation for future growth
Posted by 22-Feb-2018
-
2017, the story so far: Good growth leading to increased earnings outlook for 2017
Posted by 20-Oct-2017
-
Strong Half Year Results improve outlook for 2017
Posted by 27-Jul-2017
This week we have published the UCB Half Year Results and, in light of an impressive performance, we have updated the outlook for 2017.
-
Core medicines driving growth in 2017
Posted by 24-Apr-2017
-
Financial results: achieving growth by delivering value to patients
Posted by 23-Feb-2017
-
UCB continues to grow
Posted by 25-Oct-2016
UCB’s revenue for the first nine months of 2016 show the company continuing on its growth path driven by growth of our...
-
UCB continues to deliver on its growth strategy
Posted by 28-Jul-2016
It’s steady as she goes here at UCB despite the conditions outside. Our financial...
-
Continuing our growth path in 2016
Posted by 25-Apr-2016
The growth of UCB’s main products is driving our continued growth in 2016...
Tag cloud
- financials
- financial results
- Interim report
- Financials
- Q1
- interim report
- Financial results
- investors
- HY results
- interim results
- investor relations
- Investor Relations
- Investors
- pipeline
- AGM
- UCB
- biopharma
- strategic growth priorities
- first quarter
- Communication
- CSR
- annual report
- half-year results
- Q1 2011
- revenue
- Roch Doliveux
- Annual report
- 2010
- patient-centric
- patients